title: High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
abstract: BACKGROUND
  A paradoxical plasma HDL-Cholesterol (HDL-C) reducing effect following combined fibrate and thiazolidinediones (TZDs) therapy was recently reported in occasional cases. As HDL-C level is inversely related to cardiovascular disease (CVD) risk, we have studied the incidence of reduced HDL-C level following mono- and combined therapy with these drugs in a large diabetic population.
  
  
  METHODS
  This study was designed as a retrospective 5-year study. Lipid profile records of 54 000 diabetic patients were searched for transient reduction of HDL-C to levels lower than 17 mg/dL, which was correlated with fibrates and/or TZD treatment.
  
  
  RESULTS
  Transient reduction in plasma HDL-C to values lower than 17 mg/dL was observed in 0.02% (2/11 175) of the patients treated with fibrates alone, none of the rosiglitazone-treated patients (0/3213) and in 1.39% (9/649) of patients treated with combination of fibrate and TZD. HDL-C lowering effect was reversible upon stopping either fibrate or rosiglitazone and in some patients it occurred within 2 weeks. In two of the patients, the effect was dose-dependent.
  
  
  CONCLUSIONS
  Severe reduction in plasma HDL-C is not rare when TZD and fibrates are co-administrated to diabetic hyperlipidemic patients. As low plasma HDL cholesterol is a risk factor for CVD, the physician should be alert to this phenomenon.
authors.affiliation: Maccabi Health Care Services, Haifa, Israel. skeidar@rambam.health.gov.il
authors.forename: Shlomo
authors.initials: S
authors.lastname: Keidar
authors.forename: Hadassa
authors.initials: H
authors.lastname: Guttmann
authors.forename: Tamar
authors.initials: T
authors.lastname: Stam
authors.forename: Ilana
authors.initials: I
authors.lastname: Fishman
authors.forename: Chen
authors.initials: C
authors.lastname: Shapira
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects*; D002995:Clofibric Acid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D048909:Diabetes Complications / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002995:Clofibric Acid